The Janssen Pharmaceutical Companies of Johnson & Johnson has announced results of a new analysis showing that Invokana (canagliflozin) significantly reduced the risk of cardiovascular (CV) death or hospitalization for heart failure (HHF) in patients with type 2 diabetes (T2D) at high CV risk.
Praluent (alirocumab), an anti-cholesterol drug being developed by Regeneron Pharmaceuticals and Sanofi, has succeeded in the Odyssey Outcomes trial by decreasing the risk of death and heart attack in high-risk patients.
Novartis said that it will use Science 37's Network Oriented Research Assistant (NORA) technology in up to 10 clinical trials over the next three years.
Boehringer Ingelheim and Eli Lilly have unveiled plans to expand their clinical trial program for Jardiance in chronic heart failure with the EMPERIAL clinical trials.
Dermira said that two phase 3 clinical trials testing its acne drug, olumacostat glasaretil, failed to meet their co-primary endpoints.
Emergent BioSolutions and Valneva have commenced a phase 1 clinical trial in the US to evaluate the safety and immunogenicity of their vaccine candidate VLA1601, against Zika virus.
BerGenBio has completed enrolment of the planned 28 patients into the first stage of its Phase II clinical trial evaluating its investigational oral selective AXL inhibitor bemcentinib (BGB324) in combination with the Merck’s anti-PD-1 therapy KEYTRUDA (pembrolizumab) as a potential new treatment regimen for advanced breast cancer.
Eli Lilly and Company reported that Taltz (ixekizumab) in a phase 3b trial has helped patients with moderate-to-severe genital psoriasis in significantly reducing the impact of their condition on sexual activity.
Eli Lilly announced that Taltz (ixekizumab) has met the primary and all key secondary endpoints in COAST-V, a Phase 3 study evaluating the safety and efficacy of Taltz for the treatment of Ankylosing Spondylitis (AS), also known as radiographic axial spondyloarthritis (axSpA).
A group of investigators have demonstrated in a phase 3 clinical trial that apalutamide, an inhibitor of androgen receptor, delays spread of certain prostate cancers that had become resistant to standard androgen-deprivation therapy.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.